This content is from: Premium
Hedge Funds Loved This Investment in 2019
Managers hope 2020 is another huge year for health care and biopharma IPOs.
Unicorns may get most of the IPO headlines. But as far as some hedge funds are concerned, healthcare — especially fledgling biopharma companies — is where the action is when it comes to new issues.In 2019, 69 healthcare IPOs raised $9.2 billion, according to Renaissance Capital, a provider of institutional
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.